Table 2.

Most common (≥10%) treatment-emergent adverse events of any grade in the safety-evaluable population.

	Giredestrant 10 mg	Giredestrant 30 mg	Giredestrant 90/100 mg ± LHRH	Giredestrant 250 mg ± LHRH	All single-agent giredestrant doses	Giredestrant 100 mg + palbociclib 125 mg ± LHRH	All patients
	(n = 6)	(n = 41)	(n = 55)	(n = 9)	(n = 111)	(n = 64)	(N = 175)
Arthralgia	2 (33.3%)	10 (24.4%)	11 (20.0%)	2 (22.2%)	25 (22.5%)	14 (21.9%)	39 (22.3%)
Fatigue	2 (33.3%)	7 (17.1%)	12 (21.8%)	3 (33.3%)	24 (21.6%)	21 (32.8%)	45 (25.7%)
Back pain	2 (33.3%)	7 (17.1%)	13 (23.6%)	1 (11.1%)	23 (20.7%)	14 (21.9%)	37 (21.1%)
Nausea	2 (33.3%)	9 (22.0%)	10 (18.2%)	0	21 (18.9%)	13 (20.3%)	34 (19.4%)
Diarrhea	1 (16.7%)	5 (12.2%)	8 (14.5%)	2 (22.2%)	16 (14.4%)	18 (28.1%)	34 (19.4%)
Constipation	2 (33.3%)	6 (14.6%)	6 (10.9%)	0	14 (12.6%)	15 (23.4%)	29 (16.6%)
Cough	1 (16.7%)	3 (7.3%)	9 (16.4%)	1 (11.1%)	14 (12.6%)	14 (21.9%)	28 (16.0%)
Pain in extremity	0	3 (7.3%)	8 (14.5%)	1 (11.1%)	12 (10.8%)	7 (10.9%)	19 (10.9%)
Anemia	0	5 (12.2%)	4 (7.3%)	2 (22.2%)	11 (9.9%)	16 (25.0%)	27 (15.4%)
Bradycardia	0	3 (7.3%)	6 (10.9%)	2 (22.2%)	11 (9.9%)	18 (28.1%)	29 (16.6%)
Dizziness	3 (50.0%)	4 (9.8%)	3 (5.5%)	1 (11.1%)	11 (9.9%)	9 (14.1%)	20 (11.4%)
Vomiting	0	7 (17.1%)	4 (7.3%)	0	11 (9.9%)	7 (10.9%)	18 (10.3%)
Headache	2 (33.3%)	4 (9.8%)	4 (7.3%)	0	10 (9.0%)	8 (12.5%)	18 (10.3%)
Asthenia	0	4 (9.8%)	4 (7.3%)	0	8 (7.2%)	13 (20.3%)	21 (12.0%)
Alopecia	0	2 (4.9%)	3 (5.5%)	0	5 (4.5%)	15 (23.4%)	20 (11.4%)
Neutropenia	1 (16.7%)	2 (4.9%)	2 (3.6%)	0	5 (4.5%)	52 (81.3%)	57 (32.6%)
Thrombocytopenia	2 (33.3%)	1 (2.4%)	1 (1.8%)	1 (11.1%)	5 (4.5%)	13 (20.3%)	18 (10.3%)

Note: Data are number of patients (%).